Mao Yi-Lei, Yang Hua-Yu, Xu Hai-Feng, Sang Xin-Ting, Lu Xin, Yang Zhi-Ying, Zhang Jin-Chun, Zhong Shou-Xian, Huang Jie-Fu, Zhang Hong-Bing
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi. 2008 Apr 8;88(14):948-51.
To evaluate the sensitivity and specificity of Golgi glycoprotein 73 (GP73) for the diagnosis of hepatitis B related hepatocellular carcinoma (HCC).
Western blotting was used to detect the serum GP73level in 25 patients being HBV carrier, 24 HCC patients, 12 patients with non-liver disease, and 99 healthy controls. Serum alpha-fetoprotein (AFP) was detected by electrochemiluminescence reaction. The levels of sensitivity and specificity of serum GP73 in diagnosing HCC were compared with those of AFP. The serum GP73 levels of some HCC patients during the perioperative period were compared.
The serum GP73 level of the HCC patients, all HBV positive, was (40.36 +/- 64.43) relative units, significantly higher than those of the HBV carriers, non-liver patients, and healthy controls [(7.82 +/- 10.72), (4.48 +/- 5.70), and (2.59 +/- 5.12) relative units respectively, all P < 0.01]. There was no difference of GP73 levels between the healthy controls and the patients of non liver diseases (P = 0.2925). The sensitivity of GP73 for the diagnosis of HCC was 76.9%, significantly higher than that of AFP (48.6%). The specificity for the diagnosis of HCC of GP73 was 92.9%. Findings in a few HCC patients showed that the GP73 level remained not remarkably lowered within a week after surgical resection; but became lower 1.5-2 years after surgery. There was no raise of GP73 in the patients with non- malignant liver lesions. The GP73 levels of 4 of the 6 intra-hepatic cholangiocarcinoma patients were between those of the HCC patients and HBV carriers.
Serum GP73 has higher sensitivity and specificity in diagnosis of hepatitis B-related HCC than AFP, and it can become a new effective HCC tumor marker.
评估高尔基体糖蛋白73（GP73）对乙型肝炎相关肝细胞癌（HCC）诊断的敏感性和特异性。
采用蛋白质免疫印迹法检测25例乙肝病毒携带者、24例HCC患者、12例非肝脏疾病患者及99例健康对照者血清中的GP73水平。采用电化学发光法检测血清甲胎蛋白（AFP）。比较血清GP73诊断HCC的敏感性和特异性水平与AFP的敏感性和特异性水平。比较部分HCC患者围手术期血清GP73水平。
所有HBV阳性的HCC患者血清GP73水平为（40.36±64.43）相对单位，显著高于乙肝病毒携带者、非肝脏疾病患者及健康对照者[分别为（7.82±10.72）、（4.48±5.70）和（2.59±5.12）相对单位，P均<0.01]。健康对照者与非肝脏疾病患者的GP73水平无差异（P = 0.2925）。GP73诊断HCC的敏感性为76.9%，显著高于AFP（48.6%）。GP73诊断HCC的特异性为92.9%。少数HCC患者的研究结果显示，GP73水平在手术切除后1周内无明显下降；但在术后1.5 - 2年降低。非恶性肝脏病变患者的GP73水平未升高。6例肝内胆管癌患者中有4例的GP73水平介于HCC患者和乙肝病毒携带者之间。
血清GP73对乙型肝炎相关HCC诊断的敏感性和特异性高于AFP，可成为一种新的有效的HCC肿瘤标志物。
